Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

• Gibson C.M.
• Kastelein J.J.P.
• Phillips A.T.
• Aylward P.E.
• Yee M.K.
• Nicholls S.J.
• Pocock S.
• Goodman Sh.G.
• Alexander J.H.
• Lincoff A.M.
• Bode C.
• Duffy D.
• Heise M.
• Berman G.
• Mears S.J.
• Tricoci P.
• Deckelbaum L.I.
• Steg P.G.
• Ridker P.
• Mehran R.

Abstract

Acute myocardial infarction (MI) patients remain at high risk for recurrent events. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. Impaired cholesterol efflux is associated with higher cardiovascular (CV) event rates among both patients with stable coronary artery disease and recent MI. CSL112, a novel intravenous formulation of apolipoprotein A-I (human) derived from human plasma, increases cholesterol efflux capacity. AEGIS-II is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial investigating the efficacy and safety of CSL112 compared to placebo among high-risk acute MI participants. Eligibility criteria include age ≥18 years with type 1 (spontaneous) MI, evidence of multivessel stable coronary artery disease, and presence of diabetes requiring pharmacotherapy, or ≥2 of the following: age ≥65 years, prior MI, or peripheral artery disease. A target sample of 17,400 participants will be randomized 1:1 to receive 4 weekly infusions of CSL112 6 g or placebo, initiated prior to or on the day of discharge and within 5 days of firstmedical contact. Theprimary outcome is the timeto first occurrence of the composite of CV death, MI, or stroke through 90 days. Key secondary outcomes include the total number of hospitalizations for coronary, cerebral, or peripheral is chemia through 90 days and time to first occurrence of the composite primary outcome through 180 and 365 days.

AEGIS-II will be the first trial to formally test whether enhancing cholesterol efflux can reduce the rate of recurrent major adverse CV events.

References

1. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 (11): 1045–57.

2. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285 (13): 1711–8.

3. Berwanger O., Santucci E.V., de Barros E. Silva P.G.M., et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA. 2018; 319 (13): 1331–40.

4. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372 (25): 2387–97.

5. Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379 (22): 2097–107.

6. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. J Am Coll Cardiol. 2005; 46 (8): 1405–10.

7. Goldberg R.J., Currie K., White K., et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2004; 93 (3): 288–93.

8. Morrow D.A. Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. Circulation. 2010; 121 (24): 2681–91.

9. Remaley A.T., Amar M., Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008; 6 (9): 1203–15.

10. Tardif J.C., Heinonen T., Noble S. High-density lipoprotein/apolipo-protein A-I infusion therapy. Curr Atheroscler Rep. 2009; 11 (1): 58–63.

11. Tall A.R. An overview of reverse cholesterol transport. Eur Heart J. 1998; 19 (suppl A): A31–5.

12. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364 (2): 127–35.

13. Rohatgi A., Khera A., Berry J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371 (25): 2383–93.

14. Zhang J., Xu J., Wang J., et al. Prognostic usefulness of serum cholesterol efflux capacity in patients with coronary artery disease. Am J Cardiol. 2016; 117 (4): 508–14.

15. Liu C., Zhang Y., Ding D., et al. Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: a prospective cohort study. Atherosclerosis. 2016; 249: 116–24.

16. Guerin M., Silvain J., Gall J., et al. Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2018; 72 (25): 3259–69.

17. Soares A.A.S., Tavoni T.M., de Faria E.C., et al. HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction. Clin Chim Acta. 2018; 478: 51–6.

18. Gille A., Wright S.D., Tortorici M., et al. CSL112 restores cholesterol efflux in patients immediately after acute myocardial infarction. Circulation. 2018; 136: A16500.

19. Ray K.K., Ditmarsch M., Kallend D., et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014; 35 (27): 1792–800.

20. Siddiqi H.K., Kiss D., Rader D. HDL-cholesterol and cardiovascular disease: rethinking our approach. Curr Opin Cardiol. 2015; 30 (5): 536–42.

21. Rader D.J. Apolipoprotein A-I infusion therapies for coronary disease: two outs in the ninth inning and swinging for the fences. JAMA Cardiol. 2018; 3 (9): 799–801.

22. Nicholls S.J., Puri R., Ballantyne C.M., et al. Effect of infusion of high- density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT Trial: a randomized clinical trial. JAMA Cardiol. 2018; 3 (9): 806–14.

23. Zheng K.H., van der Valk F.M., Smits L.P., et al. HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis. 2016; 251: 381–8.

24. Nicholls S.J., Andrews J., Kastelein J.J.P., et al. Effect of serial infusions of CER-001, a pre-beta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: a randomized clinical trial. JAMA Cardiol. 2018; 3 (9): 815–22.

25. Gibson C.M., Korjian S., Tricoci P., et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein AI, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016; 134 (24): 1918–30.

26. Fournier N., Paul J.L., Atger V., et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol. 1997; 17 (11): 2685–91.

27. Diditchenko S., Gille A., Pragst I., et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol. 2013; 33 (9): 2202–11.

28. Kempen H.J., Gomaraschi M., Simonelli S., et al. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. Atherosclerosis [Electronic resource]. 2016; 255: 17–24. DOI. https://doi.org/10.1016/j.atherosclerosis.2016.10.042.

29. Rye K.A., Hime N.J., Barter P.J. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteines. J Biol Chem. 1996; 271 (8): 4243–50.

30. Easton R., Gille A., D’Andrea D., et al. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol. 2014; 54 (3): 301–10.

31. Gille A., Easton R., D’Andrea D., et al. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 2014; 34 (9): 2106–14.

32. Tortorici M.A., Duffy D., Evans R., et al. Pharmacokinetics and safety of CSL112 (apolipoprotein A-I [human]) in adults with moderate renal impairment and normal renal function. Clin Pharmacol Drug Dev. 2018; 8 (5): 628–36.

33. Tricoci P., D’Andrea D.M., Gurbel P.A., et al. Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial. J Am Heart Assoc. 2015; 4 (8): e002171.

34. Gibson C.M., Kerneis M., Yee M.K., et al. The CSL112-2001 trial: safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2018; 208: 81–90.

35. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33 (20): 2551–67.

36. Leonardi S., Lopes R.D., Steg P.G., et al. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: the CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018; 7 (2): 158–65.

37. Leonardi S., Truffa A.A., Neely M.L., et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013; 99 (17): 1282–7.

38. Tortorici M.A., Gille A., Liss C., et al. Direct augmentation of cholesterol efflux capacity in AMI patients: a PKPD substudy of AEGIS-I. Eur Heart J. 2017; 38(suppl 1): ehx502.P1106.

39. Shaw J.A., Bobik A., Murphy A., et al. Infusion of reconstituted high- density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008; 103 (10): 1084–91.

40. Murphy A.J., Funt S., Gorman D., et al. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ Res. 2013; 113: e1–9.

41. Dmitrienko A., D’Agostino Sr R.B., Huque M.F. Key multiplicity issues in clinical drug development. Stat Med. 2013; 32 (7): 1079–111.

42. Gard A., Lindahl B., Batra G., et al. Interphysician agreement on subclassification of myocardial infarction. Heart. 2018; 104: 1284–91.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)